• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Author Archive for: "Nascent Biotech"
 Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
0
By Nascent Biotech
In Corporate News, News
Posted May 4, 2022

Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors

VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology [...]

READ MORE
 Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
0
By Nascent Biotech
In News, Press Releases
Posted April 12, 2022

Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

VERO BEACH, FL / ACCESSWIRE / April 12, 2022 / Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, [...]

READ MORE
 The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial
0
By Nascent Biotech
In Science News
Posted March 8, 2022

The Laurel Amtower Cancer Institute and Neuro-Oncology Center at Sharp HealthCare to Join Innovative Antibody Brain Cancer Drug Trial

SAN DIEGO, CA / ACCESSWIRE / March 8, 2022 / Sharp HealthCare, in collaboration with Nascent Biotech, Inc, announced today, its participation in a clinical trial for a novel investigational [...]

READ MORE
 Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical
0
By Nascent Biotech
In Corporate News
Posted February 23, 2022

Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical

Milestone Payment is the Second of Four in $5M Pritumumab Licensing Deal February 23, 2022, 8:00 am EDT Dateline: Vero Beach Fl, USA Public Company Information: OTCQB: NBIO Vero Beach, Fl USA. – [...]

READ MORE
 Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted January 11, 2022

Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

VERO BEACH, FL / ACCESSWIRE / January 11, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration
0
By Nascent Biotech
In Science News
Posted July 13, 2021

Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration

SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a biotechnology company [...]

READ MORE
 Marble Arch Research Publishes Analyst Research Report on Nascent Biotech
0
By Nascent Biotech
In Corporate News, News
Posted June 15, 2021

Marble Arch Research Publishes Analyst Research Report on Nascent Biotech

VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
0
By Nascent Biotech
In
Posted June 14, 2021

Marble ARch Report – 6/10/21

READ MORE
 Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
0
By Nascent Biotech
In Science News
Posted June 8, 2021

Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology [...]

READ MORE
 Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note
0
By Nascent Biotech
In Corporate News
Posted May 4, 2021

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note

SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology [...]

READ MORE
1 2 3 4 5 6 7 8
page 1 of 8
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.